$4.24 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$27.01 - $99.95The lowest and highst price in the last 52 weeks.
-25.42xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$0.00 (0.0%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
|Market Cap||$4.24 Billion|
|Enterprise Value||$3.63 Billion|
|Dividend Yield||$0.00 (0.0%)|
|1 Year Return||+97.4%|
|Outstanding Shares||68.3 Million|
|Avg 30 Day Volume||1.45 Million|
|Earnings per Share||-$2.58|
|Price to Sales Ratio||58.71|
|Price to Book Ratio||7.34|
|Revenue to Enterprise Value||39.63|
|EBIT to Enterprise Value||-24.99|
|Total Debt to Enterprise Value||0.0|
|Debt to Equity||0.0|
|Gross Profit||$91.5 Million|
|Net Income||-$135 Million|
|Quarterly Earnings Growth (YoY)||+50.4%|
|Return on Equity||-22.01%|
|Return on Assets||-17.86%|
|Return on Invested Capital||-21.03%|
Major players in the CRISPR technology market are Thermo Fisher Scientific, GenScript Biotech Corporation, CRISPR Therapeutics AG, Editas Medicine, Horizon Discovery Plc. , Integrated DNA Technolog...Intrado Digital Media, 1 day ago
No summary available.Seeking Alpha, 11 days ago
LOS ANGELES, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Aadi) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cance...Intrado Digital Media, 12 days ago